🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Oxford Nanopore Technologies plc (LON:ONT)
United Kingdom flag United Kingdom · Delayed Price · Currency is GBP · Price in GBX
188.70
-10.80 (-5.41%)
Nov 20, 2026, 4:35 PM GMT
← View all transcripts

Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Nov 11, 2026

Summary

Native-molecule sequencing supports clinical growth, including rapid infectious-disease testing and rare-disease adoption, while direct RNA analysis opens mRNA vaccine QC and biopharma opportunities. Management targets adjusted EBITDA break-even in 2027 and >$700 million revenue by 2030.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Hi, I'm Kyle Mikson, and welcome to the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. I'm Kyle Mikson. I cover life sciences and diagnostics for Canaccord. Pleased to welcome you to a fireside chat with Oxford Nanopore Technologies here with us today. The company offers a leading sensing technology for long-read to short-read sequencing, as well as opportunities in proteomics and so forth. With us from the company, we have Nick Keher, CFO. Thanks, Nick, for joining us today. Appreciate it.

Nick Keher
CFO, Oxford Nanopore Technologies

Thank you very much for the invitation.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah, just to start, maybe just provide a brief overview of ONT and your nanopore sequencing platform for us.

Nick Keher
CFO, Oxford Nanopore Technologies

Absolutely. Oxford Nanopore, a 22-year-old company, spun out of Oxford University originally. We have 1,350 people in the company. We're FTSE 250 listed. We had a quarter of a billion sterling revenue last year. We intend to grow 23%-27% constant currency for this year to December 2026. And the platform and the technology is all based on the fact that we are the world leaders at making incredibly small holes and being able to pass through single molecules, DNA, RNA, protein. That allows us to We don't make a copy of the DNA. We don't have to cut it up into fragments. That means we see all RNA or protein, which means that we see it in its raw, native form. That means we have, we believe, the richest level of information when it comes to sequencing.

It means we can see all long-read information as well as short-read, to your point. That means we can see 100% of the genome versus circa 92% for the short-read platforms. We get the richest of information in terms of methylation. As people probably know, there is like six different types of methylation for DNA, hundreds of different types for mRNA, and many more, again, for protein. We can see all of that, and that is unique to our platform. Then on top of that, because this is not built on a platform using cameras and such, and it is an electrical-based sensing platform, we can also miniaturize the technology. This is the smallest platform that we make, which is the handheld MinION sequencer. This is used for DNA, mRNA, and protein. Within the flow cell, you have like 2,048 very small holes in this little fragment here.

Through that, we pass the DNA in this instance. It gets you about 30 gigs worth of data on this flow cell. This is the smallest device, like I say, retailing about $5,000 with five flow cells. It goes up to the PromethION range, which is circa 150 gigs of flow cell and increasing, where we run, say, 24 flow cells at a time, so about 60 genomes a week, essentially off the P24 platform itself. In a nutshell, that is the company. We aim to grow quickly this year, aim to grow mid-teens next year, and with increasing gross margins, we will hit adjusted EBITDA and cash flow breakeven in 2028. So, adjusted EBITDA in 2027, cash flow in 2028.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Perfect. Okay, that was a great overview. Now on to the kind of end market. Clinical has emerged as one of the fastest-growing end markets for you, increasing about 35% year-over-year in the first half of 2026.

What applications are driving the strongest clinical adoption today in your technology?

Nick Keher
CFO, Oxford Nanopore Technologies

At a high level, the three different buckets, if you like, in clinical that are driving the adoption are infectious disease, rare disease, and oncology. The reason for that is different for every single type, but within infectious disease, it is the fact that we have, we believe, the most, well, the accurate platform for small genomes, like bacteria, fungi, and viruses. Because we have a form factor such as this, we can miniaturize it, like we say, and because it is real-time sequencing, the turnaround time is very quick. Combining all of these factors into one means that for the infectious disease space, be it sepsis or respiratory metagenomics, we can give a turnaround time that is efficient for the physician so that they can direct therapy to the patient. You are not having to send samples off to a core lab, waiting weeks for a kind of turnaround.

We can do it for you in a four-hour period. In rare disease, it has been driven by the long-read nature of the platform and the fact that we can see more, going up to, like, on average, around 15,000 kb. We can get 100% of the genome. We can diagnose more than what you can do on the short-read. That means that we can increase the diagnostic yield for the customer, and it ends that diagnostic odyssey that patients often have in the rare disease space. Within oncology, it is a range of things, but it is the long-read capability mixed with methylation more often than not, and then also with speed on top.

A good use case is within a leukemia setting, where people need a very quick turnaround, but they need to do eight different pathology tests to be able to get the genes of interest they are looking for to diagnose accurately. We can do all of that in one run on our platform. That test consolidation is also a driving factor for economics for the lab as well, reducing costs from about $2,000 to about $500.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

All right, interesting. Across those three clinical applications, what is the Maybe one of them already has, but what has the most potential to kind of become like a clinical routine workflow the soonest?

Nick Keher
CFO, Oxford Nanopore Technologies

I mean, in the U.K., respiratory metagenomics is being rolled out now by the NHS, so I think that's already going into practice. In the U.S. and across Europe, actually, and everywhere, rare disease is really taking shape for us, and we're kind of getting uptake there by the great and the good. We announced our results that we've been selected by Natera's MyOme, essentially to be the platform of choice, so they're standardizing on us in the rare disease market, just as an example, but there are others as well. So they're kind of happening now, so into that routine setting. Reimbursement is one of those things that needs to kind of really help that adoption kind of curve increase further, and we're seeing that happen now as well.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Perfect. Then, thinking longer term, what has to happen for clinical to become an even larger portion of the business over the next several years? What's some of the largest remaining barriers? Honestly, when you think about this medium-term strap, this plan that you have, what portion, how large of a segment could this be for you?

Nick Keher
CFO, Oxford Nanopore Technologies

So it's 15% of our revenues today, but like you say, it's growing faster than the rest of the business. There's no reason why that growth rate can't continue, and this could be 20%, 30% of our business by that 2030 timeframe. That is really just what we're doing today, but we think there is a longer, bigger opportunity here for the platform when we get to the IVD setting. So we are working with Danaher, bioMérieux, and others, and we expect to add more, where essentially people are looking to kind of create an IVD standard. Once we have that will really drive considerable uptake for the product as well. So, whilst the size of the pie for clinical is arguably the biggest one that we can target, it may take. It's going to have very good growth to 2030.

It could have better growth after that.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Okay, interesting. In September of this year, you joined the Genetic Alliance's RISE Network. It's a rare disease kind of program. That might ramp later this year, early next year. Talk about that partnership and the role you expect to play there, and how important that could be in building real-world clinical evidence and pushing out this strategy you just laid out for us.

Nick Keher
CFO, Oxford Nanopore Technologies

I mean, it's really important for the patients, first and foremost, to get genomics highly adopted to stop that diagnostic odyssey for those patients who have got rare disease. So first and foremost, it's about the patient. But absolutely, it's also about gaining that real-world evidence, because clinicians will switch when they can see the benefits. And whilst people in the know know, we need to gain a more globally recognized data set that essentially means that when our sales teams go and speak to customers, physicians in the field, it's very clear that they should be using this as the platform of choice. So yes, we think we have a lot to offer in this space because of the nature of our platform and what it can do.

Joining the RISE initiative is only going to embed in that, within that network, and we hope to be able to get that data set together so that it can be adopted more universally as well.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Does this turn into any meaningful financial contribution for you?

Nick Keher
CFO, Oxford Nanopore Technologies

It is costing a lot, I can tell you that. Whether it is a meaningful investment from our side, it should drive a next wave of growth. Like these sort of investments, you are not doing it for a year one kind of return. You are doing it for the clinical utility benefit that will come, and so it has got a very long tail to it.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Okay. Now turning to biopharma, that end market, Eva, for years, you have identified that segment as an important contributor to your long-term growth objectives. What applications within biopharma are generating the greatest interest among biopharma customers today, and what do you see as the most significant opportunities for expanded adoption in here?

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah. I think everybody understands the use of sequencing within, say, target ID drug discovery. Absolutely we are used there as well. Because we give that riches of information, we are still at very early days of that adoption curve. I used to work, like previous role, as a drug discovery AI company, and we used to spend a lot on buying data. Essentially that was to pull together different data sources, run AI over it to predict how to treat disease and target ID, essentially. We are feeding into all of that, and that is essentially where we are playing today. What we are also seeing is a lot of interest because of our direct capability, direct mRNA capability, and particularly in the mRNA field. A little segue, I am going to monopolize a bit of time on this because I think it is important.

Everybody has seen the data for the mRNA personalized cancer vaccines and how important that is going to be. I am not sure people necessarily fully realize our role here, because everybody is thinking about, you get the patients, you get the sample, you sequence the tumor, you create the mRNA vaccine. Actually, there is a quality control step at the other side as well. Whilst we could be used as a platform in the sequencing space to sequence the tumor, we are absolutely going to be used as the quality control step. There are five actually critical quality attributes within identity, purity, integrity, and we are going to be used across all three. We hope to be part of a BLA filing shortly. When we are, we think this could be a sizable market opportunity for us because we can look at the RNA directly.

We can see the modifications in the vaccine to know that you know what you've made is correct. You know that it's identity, integrity, purity at the right levels. Today, we're saying, we can see that list price is around $2,000 per test, and every test is a batch, and every batch is a patient. People are talking about melanoma being, say, 25,000 patients. You can do the maths pretty quickly on it. With discounting, maybe we're more like $1,000, but that's only for the first critical quality attribute of identity. We're going to be adding on integrity and purity over the course of the next six to 18 months because we've got different phases of launch, and we're being used by all the companies here. This is not just a bet on a single company.

It's really kind of looking at the entire field of mRNA vaccines and going, "How is Nanopore going to play in this, in the personalized cancer space?" We are on the quality control step. We think this is really sizable, very exciting. Not sure the market's fully appreciated how big it could be, but hopefully they will do when filings happen. Then, just sorry, like beyond that, we've clearly got other workflows as well, so it's not just one workflow we're looking at. The other ones, we think sterility testing for us. You think about infectious disease, what you're trying to do is take a sample of blood, get rid of the host DNA, and then look at what's left. Now, in infectious disease, PCR testing, you've got to go fishing with a rod.

You've got to know exactly the fish you're going for, and you've got a set out panel. For us, we're going fishing with a net. We capture everything, and we can tell you what is in there, every single bug. Is it alive? Is it replicating? And what to do. So in sterility testing in biopharma for biologic drug production, all biologic drugs, we could have a role to play, and that is a very sizable market as well. So we've got partnerships with Lonza in the CDMO space, but we're going directly to the end market customers as well. We've got ongoing conversations with the CROs. We can see a lot of interest building around all of this, and so that's why we think by 2030, biopharma, 8% of revenues today, it could be our biggest segment, bigger than research and government, which is 65% today.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah, really interesting. Sterility is intriguing for sure, but on the mRNA, QA/QC side, that sounds super exciting, obviously, but maybe just talk about why another sequencing platform.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

You wouldn't be able to compete with you there, why you're differentiated on that area particularly.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah, so in identity testing, what we're replacing there is, for one of the CQAs out of five, is Sanger. So, that 40-year-old technology that's very good, still does a lot of revenue for Thermo, but scaling is an issue. If you want to use that test and then you want to do 100,000 batches in a year, for instance, it's going to be pretty difficult. It's going to be very labor-intensive, very expensive, very long. Now, for us, because we can do not just that test, but consolidate several other orthogonal tests into one setting, and those five critical quality attributes that you could only see on our platform because you have to look at the mRNA directly, we're going to be replacing the need for HPLC, mass spec, gels, and Sanger, and all these other things, several orthogonal tests into one on our platform.

The big thing here, vein-to-vein time. So we shrink the time. Whilst it could take weeks to do it on all these other platforms, you can do it in days and hours. For the customers, that's kind of important because it's important for the patients. For the other sequencing players, they can't look at the mRNA directly, so they can't see these modifications. We're the only company that can see methylation in mRNA, and there's hundreds of different types. This is essentially another form of that. So our ability, our unique ability to look at mRNA directly unlocks this for us. Our unique ability to consolidate multiple different test types, because we're a sensing platform, not another sequencing company, into one, means that we essentially can do something here that those other platforms just can't do.

We feel very confident about defending our place here, and if you need any more, once it's written into the BLA, it's pretty hard to get out of it as well.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah, I cannot really pick apart that explanation much, honestly. That is perfect. Just moving on to another exciting development from your mid-year trading update, I guess. You announced this cross-licensing agreement with a global diagnostics company, a company that you do not have a past partnership with, so it is not bioMérieux, it is not Danaher, it is someone else. It includes a $20 million upfront licensing fee, $15 million committed purchases for products and so forth, and then a longer-term royalty component that I think is like 90% of the deal value. Maybe discuss the strategic rationale behind that agreement and what it means for the broader commercialization of nanopore sequencing, and there is this IP component that I think might play into this a little bit too.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah, absolutely. First of all, conversations with that company, who has been buying product for many, many years. Essentially, it really started in earnest about 16, 18 months ago now from today. The first six months of the year, conversations really started to get more intense. The negotiations really took another turn. Now, it is a cross-licensing arrangement, essentially, where we sat down with the other party. We have essentially gone through our IP, and essentially our capabilities. They have got their side and their IP as well. The net of that is that we have reached an agreement whereby they would pay us $20 million, buy $15 million worth of product, as you say, over two years, and a low to mid single-digit royalty where we see, like you say, 90% of the value being in that tail.

That is from an NPV perspective and use a discount rate of about 15%, so it is considerably more from a cash perspective. Now, the strategic rationale for this, we actually think we cannot name the company. Hopefully one day they are happy to talk about it more openly. We actually think there is a potential here for something bigger over time than even what the financials on the table are today, because we see a symbiotic relationship opportunity. So we are hoping that over time this builds into something more. Strategically, we think it is completely on point. From a commercial aspect as well, it shows that we are open to doing these sorts of cross-licensing arrangements, and that we are being more commercial in our thinking around this as well. So we are very happy with it.

We think it can build into something greater over time, and we think the market is not quite realized and understood it yet. Hopefully over time it will, and people will see that when we have got those targets out there for greater than $700 million by 2030, greater than 15% EBITDA margins by 2030, that is excluding this. This could add quite a considerable number to the bottom line when we come to 2030 as well.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Right. It's 100% margin, basically, right?

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah, so you don't need to really give us too many details on this partner, right? But there are many potential vendors to collaborate with for short-read sequencing, and you're one of the only ones for long-read. So I imagine that this partner probably benefits or gains something from your long-read aspect. Is there anything to read into that? Like maybe within nanopore long-read, they're thinking about this in some way, diagnostically or otherwise?

Nick Keher
CFO, Oxford Nanopore Technologies

I like the way you're going, so yes. Also from the direct capability, so methylation. We could do a lot. We're very open about the fact that we could do a better job of, and we will do, of explaining the utility of the product from a methylation long-read perspective, and that you can see the customers are adopting it. We're growing very quickly relative to the rest of the market, but we think we could do better. Like I say, the people in the know, and that's, there aren't that many global diagnostic companies out there, but we've signed partnerships now or deals with quite a few of them, and they see the value. It's exactly on that line where I think that symbiotic relationship comes down that path as well.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah. Okay, great. We don't have a ton of time, so maybe just on the pipeline and the technology roadmap. You've launched or aim to launch a bunch of products and new kind of applications over the next few years. What's going to have the most impact on customer adoption over the next several years across the end markets?

Nick Keher
CFO, Oxford Nanopore Technologies

Bioinformatic workflows. The technology, the flow cells themselves, we reached a level of accuracy that essentially means that that's a meme now, and essentially we're good enough, essentially. We crossed that hurdle, and we've got to a good place there. The next hurdle came robustness of the platform, in all honesty, and we've nailed that one. The flow cells themselves, I see the data on a daily basis and review it on a monthly basis. The quality is just, it really stepped up, and it has done for the last year, and the customers are saying the same thing. The next thing is, how do we ensure that it's the easiest platform to use as well? And that comes down to the bioinformatics support that's there as well.

This is like the analogy of we think we make the best computer, but have we got the apps on it? An Excel spreadsheet, a PowerPoint presentation capability, things like that. We're going to add on this capability. We launched today the Adaptive Sampling software option as well. Go have a look on the website, and we're very happy with that. We think it's a real unique capability. Well, it is unique to our platform. You're going to see more of this. You're going to see more software-ready, like product offerings for the customer so they can adopt it, turn it on, go do it, and it's going to be easier for them to set it up. Now, that's all great. There are other things that we'll do in terms of more kits as well, because you've got the bioinformatics at the back end.

You're going to need kit preparation to be right as well. We're going to focus a bit on that. We're going to allow people to do more on the flow cell, so increasing high throughput barcoding requirements so that customers can actually get more off a flow cell. It brings down the cost for them, and it means that we can target greater market segments, because there are about five workflows on Sanger, for instance, which is doing that $ 1 billion, where we're kind of ticking them off. And if we get high throughput barcoding kit, we think we kind of tick off the last one, and that means we can kind of grow revenues even quicker again.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Okay. Yeah. That's great. And the Adaptive Sampling app, the workflow and informatics is very important, so that's great to hear that's launched. I guess just thinking about the financials kind of near term. We're already pretty close to the calendar year end, but we're thinking about next year. How do you see the geographical regions kind of playing out for you with respect to like Asia, EMEA, and then the Americas, and any interesting kind of like different aspects that are affecting you and maybe not the other sequencing vendors?

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah. It is really difficult for us to talk in the grand schemes of like the whole market because there is an 80-pound gorilla in the room, which is 180 lbs, which is Illumina. So they are the bellwether for the market. We said 23%-27% top line constant currency growth. The market consensus has kind of got us around the 23%, which is from a CFO perspective, great. Everybody is like, model the low end of the guide, absolutely fine, and that is where we want everybody to be. In terms of the regional performances, we said at the first half, and it has kind of played out the way we saw it, EMEA did incredibly well in the first half, but it had a tough comp going into the second half, so we expected growth rates to come down a little bit, and that is what we will see.

That region continues just to kind of deliver as well. In Americas, we expected the second half growth rate to improve because we had a lot of companies evaluating us, particularly in the clinical field, that have now adopted and are ramping. So that is what we expected to see in the second half. That is what we are seeing in the second half. In APAC, we had issues in China, and that is from an export control restriction perspective. It is the same. So we said it was going to be the same. It has been the same. It is a tough market for us at the moment, but we hope with the reorganization that we are doing of our team on the ground as well, we can kind of move that into a better place for next year. That is the plan.

The rest of the region overall, it is not Oh, yes, I lost my train of thought there. It had a tough comp in the first half because of the PRECISE II contract rolling off. It does not have the same thing in the second half. So, Americas, a better second half. APAC, a better second half. EMEA, maybe a little bit lower. That is how we are kind of seeing it play out. The consensus has us at GBP 270.7 million of revenue for this year. I think it is a good place to be.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

That is great. Geographically, are you kind of winning in the clinical side anywhere in particular? There is one competitor of yours that talks a lot about the EMEA clinical performance, but kind of lagging in the U.S. Anything like that going on?

Nick Keher
CFO, Oxford Nanopore Technologies

We are doing really well in the U.S. But we are also doing well in EMEA. We are now twice the size of the other long-read player in reality. They have got a very good platform. In certain application areas, we think it is a really good fit for their platform, actually, so all hands off to them. But we are seeing that adoption, and we are growing very quickly in it as well. So, it is not just Americas, it is also EMEA, and it is also APAC. Yeah, it is a bit everywhere, I am afraid.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

No, don't be afraid.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah, sorry.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

That is a good problem to have. In the last minute or two, you talked about the $700 million—

Nick Keher
CFO, Oxford Nanopore Technologies

Target.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

—2030 target for revenue, and let's just assume, let's just peg that there, just keep that there. You also have the EBITDA positivity target of 2028, and I think cash flow as well in that year.

Nick Keher
CFO, Oxford Nanopore Technologies

Oh, no, EBITDA 2027, cash flow 2028.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Okay, so very—

Nick Keher
CFO, Oxford Nanopore Technologies

No downgrade here.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Very soon. Let us just clarify that. So, very soon. And you are getting there. I think in our model, for example, you are pretty close. It is not that challenging. But to grow at these rates, obviously, you are probably going to have to invest and stuff. So, maybe just walk through what gives you confidence in these profitability targets, as well as what happens to gross margin and R&D and marketing and stuff as well.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah, absolutely. So, this year, we have guided the market to 62% gross margins before the one-off, the $20 million one-off, which influences it more towards that 64 level. And we have said that we expect revenue growth at the top line, so 23%-27% constant currency, and adjusted OPEX to basically negative, like flat to negative a little bit. We did better than that in the first half, and actually, we showed a 54% reduction in adjusted EBITDA loss. People are kind of, the market is starting to believe us that actually, yeah, that break-even is possible for next year.

It is because if we can grow the top line at mid-teens next year, which looks eminently possible given our track record, if we can increase our gross margins again by circa 200 basis points, 300 basis points, and if we can keep costs barely flat to single-digit growth with an increasing D&A charge, then we are going to hit EBITDA break-even. So, it is on track for all of that, and that is going to be a big moment for the company, one of the few tools companies that is kind of made it through the chasm to the other side.

Then, the things that can change from there is about the scale of investments we can start to make thereafter, because adjusted EBITDA target of greater than 15% before the royalty by 2030, if you look at the revenue number, it actually implies quite a lot of investment as well.

So, we have modeled this, like, greater than $ 700 million. So, if it is $ 700 million, it is the same cost base as if it is $ 800 million, $ 900 million, because we are assuming that we are going to invest pretty substantially, actually, because the last year, we did two restructurings last year. We have really focused our efforts in R&D and on our commercial infrastructure, 450 people. We could support a revenue line that is 2x where we are today.

So, we have got all the right bums on seats, people in places. It is about sweating the assets. But absolutely, we can see that we could even step up the investments now as well. So, you may start to see that happen from 2028 onwards. And yeah, sales and marketing in particular, we already spend quite a lot. So, if anybody is listening at base camp on this, then there is no more.

But we are already making substantial investments in the company. It is about scaling it now.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Yeah, I think that the financial targets to 2030 are pretty reasonable, honestly.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

And investors reacted pretty well, at least the events that we got. That was great. I guess finally, before we wrap up, anything that we did not cover that you want to touch on, including, obviously, there is a lot of We touched on competitive stuff a little bit, but there is more sequencing companies and news flow each day, it seems like, right? And you mentioned some long read. There has been some long read with rare disease, there has been some kind of competitive news as well. So, anything that we did not touch on that you want to talk about, including that aspect?

Nick Keher
CFO, Oxford Nanopore Technologies

No, look, I think we covered all the key highlights. What I would say is that we have not necessarily talked a lot about protein today. And I think over the next six, 12 months, you are going to hear more from us on that, because within our peptide sequencing capability and our whole protein, full-length protein, essentially, capability as well, in both areas, we made a lot of progress. So, actually, over the next six, 12 months, you are going to hear more. And I think that is going to be quite interesting, because on the one platform, you are going to have truly multiomic capability of DNA, RNA, protein, and a greater understanding of biology as a whole. That is going to make us quite attractive.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

One little question about that. Proteomics, that is obviously a research application right away, but does that ultimately help in the biopharma or clinical world too?

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah. We have already mapped out the end market customers, and in particular, biopharma and clinical are key. In fact, the biggest. It will be a research application at the start, but we have about five target applications, three within peptide sequencing, two within whole full-length protein. And yeah, the market sizes vary. It is bigger within whole protein, and it is absolutely biopharma clinical, the kind of key use cases.

Kyle Mikson
Managing Director and Senior Research Analyst, Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Excellent. Okay. We have to cut it there, but thanks a lot, Nick, for joining us. It was great.

Nick Keher
CFO, Oxford Nanopore Technologies

Thank you very much. Cheers.